Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chelsea Therapeutics International has acquired full global rights to the I-3D portfolio of orally active, dihydroorotate dehydrogenase inhibiting compounds for the treatment of autoimmune diseases and transplant rejection.
Subscribe to our email newsletter
Following a decision to focus its resources on its immunomodulatory compounds, Active Biotech has discontinued its participation in the I-3D co-development program and granted Chelsea exclusive global rights to the portfolio in exchange for royalties on future sales.
The I-3D portfolio, originally developed by Active Biotech and under joint development by both companies since 2006, consists of an extensive library of therapeutic compounds that have demonstrated, during preclinical testing, potent inhibition of dihydroorotate dehydrogenase (DHODH) activity while maintaining PK and safety properties superior to the marketed DHODH inhibitor. Potential indications for drug candidates in this library include transplant rejection, rheumatoid arthritis, psoriasis and systemic lupus erythematosus.
Simon Pedder, president and CEO of Chelsea, said: “We continue to believe that the I-3D portfolio of DHODH inhibitors may have value and have identified a cost-effective process for screening molecules in this portfolio which will require only a minimal investment of time and money.”